I am a
Home I AM A Search Login

Papers of the Week

Papers: 1 Oct 2022 - 7 Oct 2022

Pharmacology/Drug Development


2022 Oct 03

Pain Manag

Focus on zavegepant: the first intranasal third-generation gepant.


Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti M T
Pain Manag. 2022 Oct 03.
PMID: 36189708.


Migraine is the leading cause of years lived with disability in people under 50 and its burden is increased by calcitonin gene-related peptide (CGRP)-driven chronicity. Newly approved small molecules that antagonize the CGRP receptor, gepants, have advanced from the hepatotoxic first-generation telcagepant to third-generation intranasal zavegepant; during this process of drug development, rimegepant, ubrogepant and atogepant, which are orally administered, have been launched and approved for clinical use with no warning for hepatotoxicity. Real-world, long-term postmarketing data about the efficacy and safety of gepants are awaited. The aim of the present drug evaluation study was to provide an overview of the novel, third-generation intranasal Zavegepant, encompassing its development and future perspectives.